325 related articles for article (PubMed ID: 35402579)
1. Genome-wide screening and immune landscape suggest a potential-m6A-related lncRNA risk signature for predicting prognosis of melanoma.
Shen K; Wang H; Xue S; Wang L; Ren M; Gao Z; Wei C; Gu J
Ann Transl Med; 2022 Mar; 10(5):241. PubMed ID: 35402579
[TBL] [Abstract][Full Text] [Related]
2. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
5. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
6. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
[No Abstract] [Full Text] [Related]
7. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
8. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
10. N6-Methyladenosine-Related lncRNAs Are Novel Prognostic Markers and Predict the Immune Landscape in Acute Myeloid Leukemia.
Zhang L; Ke W; Hu P; Li Z; Geng W; Guo Y; Song B; Jiang H; Zhang X; Wan C
Front Genet; 2022; 13():804614. PubMed ID: 35615374
[No Abstract] [Full Text] [Related]
11. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
12. Identification of m6A-related lncRNAs-based signature for predicting the prognosis of patients with skin cutaneous melanoma.
Lin W; Tan ZY; Fang XC
SLAS Technol; 2024 Feb; 29(1):100101. PubMed ID: 37541541
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Ferroptosis-Related LncRNA Signature for Predicting Prognosis and the Immune Landscape Features in Uveal Melanoma.
Ma X; Yu S; Zhao B; Bai W; Cui Y; Ni J; Lyu Q; Zhao J
Front Immunol; 2022; 13():922315. PubMed ID: 35774794
[TBL] [Abstract][Full Text] [Related]
14. m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer.
Li Z; Li Y; Zhong W; Huang P
J Oncol; 2021; 2021():7488188. PubMed ID: 34349798
[TBL] [Abstract][Full Text] [Related]
15. The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.
Huang H; Wu W; Lu Y; Pan X
J Thorac Dis; 2022 Oct; 14(10):4055-4072. PubMed ID: 36389308
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
Wang JM; Li X; Yang P; Geng WB; Wang XY
BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
[TBL] [Abstract][Full Text] [Related]
17. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract][Full Text] [Related]
18. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
19. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
Front Oncol; 2022; 12():774307. PubMed ID: 35141159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]